Scarica l'app Stockscreener
2.05
5.67%
0.11
Pre-mercato:
2.09
0.04
+1.95%
Nuvation Bio Inc Borsa (NUVB) Ultime notizie
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com
Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks
Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE
Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter
Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN
Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus
Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive
Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks
Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa
US FDA approves Nuvation Bio’s lung cancer therapy - WSAU
US FDA approves Nuvation Bio's rare lung cancer drug - Reuters
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZ - GuruFocus
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Benzinga
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung - GuruFocus
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtrozi | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib - Investing.com
Nuvation Bio (NUVB) Trading Resumes | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung Cancer | NUVB Stock News - GuruFocus
Nuvation Bio scores first FDA approval for new lung cancer drug - Endpoints News
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer - GuruFocus
Nuvation kinase inhibitor wins FDA approval in non-small cell lung cancer - TipRanks
Nuvation Bio stock in focus as FDA clears Ibtrozi (NUVB:NYSE) - Seeking Alpha
Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC - TipRanks
FDA Grants Approval to Nuvation Bio's Ibtrozi for Lung Cancer Treatment (NUVB) | NUVB Stock News - GuruFocus
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Mid Florida Newspapers
Nuvation Bio (NUVB) Shares Surge Following FDA Approval | NUVB Stock News - GuruFocus
US FDA approves Nuvation Bio's lung cancer therapy - TradingView
Nuvation Bio Stock Trading Halted, Pending Material News Release - marketscreener.com
FDA announces apporval of Nuvation Bio’s Ibtrozi for lung cancer - TipRanks
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio: Judgement Day Grows Closer (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NYSE:NUVB) Raised to “Hold” at Wall Street Zen - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Shares Sold by Squarepoint Ops LLC - Defense World
NUVB Stock Price and Chart — NYSE:NUVB - TradingView
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):